Next Science (ASX:NXS) has received a warning letter from the US Food and Drug Administration (FDA) following an inspection of its Jacksonville, Florida facility in August and September 2024, according to a Tuesday filing with the Australian bourse.
In its letter, the FDA determined that the company's Xperience, Blastx, and Surgx products did not have premarket approval related to certain marketing and labeling claims, the filing said.
The FDA also identified potential quality system violations during the inspection of the facility.
The company has implemented corrective actions and is working with the FDA to resolve the matters, while a follow-up inspection will be required to assess progress, the filing added.
Shares of the company fell past 8% at market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.